Description
Name: CJC-1295 (Modified Growth Hormone Releasing Hormone Analog) / Ipamorelin (Growth Hormone Secretagogue Pentapeptide)
Sequence: CJC-1295: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Gln Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Molecular Formula: CJC-1295: C₁₅₂H₂₅₂N₄₄O₄₂ Ipamorelin: C₃₈H₄₉N₉O₅
Molecular Weight: CJC-1295: ≈ 3367.93 g/mol Ipamorelin: ≈ 711.86 g/mol
CAS Registry Number: CJC-1295: 863288-34-0 Ipamorelin: 170851-70-4
CJC-1295/Ipamorelin– SYNERGISTIC RESEARCH PEPTIDE COMBINATION FOR GROWTH HORMONE SIGNALING STUDIES
Scientific Overview of CJC-1295/Ipamorelin
CJC-1295 and Ipamorelin are complementary research peptides commonly evaluated together in in-vitro and in-vivo experimental studies exploring the regulation of the growth hormone (GH) axis.
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analog.
Ipamorelin is a selective ghrelin receptor agonist (GHSR agonist) studied for its ability to stimulate GH release through independent but converging pathways.
Research examining this peptide combination has focused on:
• Synergistic GH Axis Modulation – comparative analysis of pituitary signaling and pulsatile GH release (Teichman et al., 2006)
• Receptor Specificity and Selectivity – study of CJC-1295 binding to GHRH receptors and Ipamorelin activation of GHSR-1a pathways (Depoortere et al., 1997)
• Endocrine Signal Integration – investigation of combined effects on cAMP and intracellular calcium signaling cascades (Frohman et al., 2001)
*This peptide is intended solely for laboratory research use. It is not approved for human consumption or therapeutic application.
COA for this item
Reviews
There are no reviews yet.